|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ПсковГУ |
||
Aptamers as a new frontier in targeted cancer therapyстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus- Авторы: Yingying Li, Zamay Tatiana N., Luzan Natalia A., Pryakhin Evgeny A., Styazhkina Elena V., Osminkina Liubov A., Kolovskaya Olga S., Dymova Maya A., Kuligina Elena V., Richter Vladimir A., Bkhattachariia Alena G., Bydanov Dmitry A., Galantsev Alexander V., Vostrov Ivan A., Liu Zhenbao, Zamay Galina S., Kichkailo Anna S., Wang Xue-Qiang
- Журнал: Advanced Drug Delivery Reviews
- Том: 226
- Год издания: 2025
- Издательство: Elsevier BV
- Местоположение издательства: Netherlands
- Номер статьи: 115692
- DOI: 10.1016/j.addr.2025.115692
- Аннотация: Cancer treatment has transitioned from traditional chemotherapy to the molecular medicine era, emphasizing personalized therapy at the molecular level. Aptamers, also known as ’chemical antibodies’, play a pivotal role in advancing molecular medicine. Utilizing the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique, these aptamers exhibit exceptional affinity for a wide range of targets, ranging from picomolar to nanomolar levels. Their exceptional characteristics, including ease of preparation, small size, low immunogenicity, remarkable chemical stability, and convenient modification, make them highly versatile for precise cancer therapy. Notably, aptamers have been successfully combined with therapeutic agents, such as small interfering RNAs (siRNAs), microRNAs (miRNAs), and small molecule toxins for diverse research purposes. This review article will primarily focus on recent progress in aptamer-based targeted therapy for cancer, offering readers a comprehensive insight into the latest developments in aptamer-based cancer treatment.
- Добавил в систему: Осминкина Любовь Андреевна